Athenex Inc (NASDAQ:ATNX)
| 11.09 Delayed Data As of Jan 15 |  -0.57 / -4.89%Today’s Change | 5.63 Today|||52-Week Range 15.73 | +0.27% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $1.0B |
Company Description
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves in the sales and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.
Contact Information
Athenex, Inc. 1001 Main Street Buffalo New York 14203 |
Employees
Shareholders
| Other institutional | 39.54% |
| Individual stakeholders | 32.03% |
| Mutual fund holders | 19.20% |
Top Executives
| Yiu Nam Lau | Chairman & Chief Executive Officer |
| Jeffrey M. Yordon | COO & President-Athenex Pharmaceutical Division |
| Randoll Sze | Chief Financial Officer |
| Rudolf Kwan | Chief Medical Officer |
| David Cutler | Vice President-Clinical Development |
